US2017203013A1PendingUtilityA1
Reducing post-operative adhesion formation with intraperitoneal glutamine
Est. expiryAug 11, 2025(expired)· nominal 20-yr term from priority
Inventors:Adebola O.E. Obayan
A61P 41/00A61P 17/02A61K 9/12A61L 2300/214A61K 31/198A61L 31/16A61L 31/10A61L 31/148A61L 2300/412A61K 38/05A61L 31/047A61L 2300/252A61L 31/145A61K 9/0024A61L 2300/25A61K 9/0019A61L 2300/424
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A composition for intraperitoneal administration comprising a pharmaceutically acceptable carrier and at least one glutamine source.
2 . The composition of claim 1 , wherein the at least one glutamine source is a soluble peptide containing L-glutamine.
3 . The composition of claim 2 , wherein the soluble peptide is a dipeptide.
4 . The composition of claim 3 , wherein the dipeptide is alanylglutamine.
5 . The composition of claim 1 , wherein the at least one glutamine source is L-glutamine.
6 . The composition of claim 1 wherein the composition is formulated as a gel.
7 . The composition of claim 1 , wherein the composition is impregnated in a surgical material.
8 . The composition of claim 7 , wherein the surgical material is a mesh.
9 . A medical device comprising the composition of claim 1 .
10 . A delivery device containing the composition of claim 1 , wherein the device is for delivery of the composition intraperitoneally during surgery.
11 . A method of treating a patient to reduce post-operative adhesion formation comprising intraperitoneal administration of an effective amount of a glutamine source to said patient.
12 . The method of claim 11 , wherein the glutamine source comprises L-glutamine amino acid.
13 . The method of claim 11 , wherein the glutamine source comprises a soluble peptide containing L-glutamine.
14 . The method of claim 13 , wherein the peptide is a dipeptide.
15 . The method of claim 14 , wherein the dipeptide is alanyl-glutamine.
16 . The method of claim 11 , wherein the glutamine source is delivered to the peritoneal cavity during surgery.
17 . The method of claim 11 , wherein the glutamine source is in a gel formulation.
18 . The method of claim 11 , wherein the glutamine source is placed on or is impregnated in a surgical material or an implantable medical device.Join the waitlist — get patent alerts
Track US2017203013A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.